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Background. Cytomegalovirus (CMV) infection directly targets vascular endothelium and smooth muscle and
at older ages is associated with accelerated vascular pathology and mortality. CMV-speciﬁc cellular immunity might
directly contribute to this process.
Methods. Conventional ex vivo activation–induced T-cell responses to 19 dominant CMV antigens, along with
CMV-speciﬁc inducible regulatory-type CD4+ T cells (iTregs), were measured in healthy older people, using a novel
protocol that included classic Treg markers alongside the activation marker CD134. Measurements were correlated
with diastolic, systolic, and mean arterial blood pressure, a surrogate marker for arterial stiffness.
Results. CMV-speciﬁc iTregs recognized the same antigens as conventional CD4+ T cells and were signiﬁcantly
more frequent at older ages. They suppressed antigen-speciﬁc and nonspeciﬁc proliferation and in large part ex-
pressed Foxp3. Frequencies of CMV-speciﬁc iTregs and CD8+ T cells (summated response) were signiﬁcantly asso-
ciated with diastolic and mean arterial pressures. Confounders, including age, body mass index, smoking,
antihypertensive medication use, or C-reactive protein levels, did not explain these observations.
Conclusions. A novel CMV-induced regulatory-type CD4+ T-cell subset is readily detectable in CMV-infected
people and, like the aggregate CD8+ T-cell response to the most dominant CMV antigens, is quantitatively associat-
ed with arterial stiffness in older life. Whereas CD8+ effector T cells might directly cause vascular injury, iTregs may
attenuate this response.
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Since the 1990s, cytomegalovirus (CMV) infection has
been implicated in vascular pathology and immunose-
nescence [1–5]. CMV directly targets endothelial and
smooth muscle cells and is found in vascular lesions,
where it might, directly or indirectly, contribute to pa-
thology [3–13].Moreover, after onset of CMV infection,
endothelial cells upregulate class I major histocompati-
bility complex (MHC) molecules, rendering them more
vulnerable to CMV-directed cytotoxicity [14, 15].
In the context of human immunodeﬁciency virus
(HIV) infection, immunosenescence and vascular pa-
thology are observed at earlier ages [16], and associa-
tions of these conditions with CMV/HIV coinfection
have been subject to intense investigation recently [17].
A number of clinical studies have suggested a role of
CMV-speciﬁc T-cell immunity in vascular changes. For
example, Parrinello et al [18] reported that higher anti-
CMV antibody titers are associated with carotid artery
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lesions in HIV-positive individuals who became aviremic after
they initiated highly active antiretroviral therapy, implying that
T-cell reconstitution contributes to this association.Addingmore
concrete evidence of T-cell involvement, Hsue et al [19] ob-
served that that carotid intimamedia thickness is directly related
to the size of a CMV protein–speciﬁc CD8+ T-cell response in
both HIV-positive and HIV-negative individuals. It appears
from the literature to date that a role of CMV-speciﬁc CD8+ ef-
fector T cells in causing or aggravating vascular injury is highly
likely. However, the role of CD4+ T cells is still very unclear.
Among CD4+ T cells, inducible regulatory T cells (iTregs) are
of speciﬁc interest, because they are thought to be induced by
the same antigens as conventional T-cell responses and may be
involved in attenuating the immune response. In hepatitis, for
example, iTregs are thought to protect vital tissue but also reduce
viral clearance and so promote chronic infection [20, 21].
After onset of CMV infection, iTregs might limit acute vas-
cular damage caused by effector T cells. This would be in agree-
ment with ﬁnding in a recent publication demonstrating that
Tregs can attenuate atherosclerosis in a mouse model [22]. Un-
fortunately, no speciﬁc marker of iTregs is available for tracking
them in the same way as Tregs more generally.
Here, we aimed to identify iTregs by combining the classic
Treg markers CD25 and CD39 [23, 24] with a short-term acti-
vation marker, CD134 (OX40) [25]. Whereas the expression of
CD25 and CD39 converges on strongly suppressive Tregs, co-
expression of CD25 and CD134 following 48 hours of antigen
stimulation identiﬁes antigen-speciﬁc, activated CD4+ T cells
[26]. The goal of combining all 3 markers was to identify iTreg-
type CD4+ T cells and, to be comprehensive, we used a range of
different CMV antigens for stimulation (CMV lysate and 6 dif-
ferent peptide pools spanning the CD4 target proteins UL83,
UL55, UL86, UL99, UL153, and UL32) [27, 28]. To capture
CMV-speciﬁc CD4+ and CD8+ effector T-cell responses at the
same time, we additionally studied the short-term activation
markers CD154 upregulation, degranulation, and interleukin 2
(IL-2), tumor necrosis factor α (TNF-α), and interferon γ
(IFN-γ) production among CD4+ and CD8+ T cells following
overnight stimulation in a uniquely comprehensive approach,
using the aforementioned 6 plus 13 additional CMV target an-
tigens (Table 1) [28].
CMV-speciﬁc CD4+ T cells matching our deﬁnition of iTregs
were common in CMV-infected people and displayed the hall-
mark features (phenotype and function) of Tregs. Their levels
were signiﬁcantly increased in older people, particularly older
women, and correlated with levels of CD8+ effector T cells.
Linear regression analysis including pertinent covariates such
as age, body mass index (BMI; deﬁned as the weight in kilo-
grams divided by the height in meters squared), blood pressure
medication use, smoking, and inﬂammation (ie, C-reactive
protein [CRP] levels) demonstrated a signiﬁcant association
between CMV-speciﬁc T-cell subsets (CD8+ T cells and iTregs)
and diastolic blood pressure, as well as mean arterial blood
pressure, which is an established surrogate marker for vascular
stiffness [28].
METHODS
Donors
We recruited 131 healthy older volunteers (age, 60–85 years)
from general practices and 55 healthy young people (age, 20–35
years) from a population of university students and staff (>90%
of study participants were white, and the remainder were black
African or Asian). After a participant provided written informed
consent, a trained research nurse recorded vital signs, including
heart rate and body temperature. A standardized brachial blood
pressure measurement was performed for each participant after
they had rested for 10–15 minutes in a seated position, using an
Omron 705CP automated blood pressure monitor (Omron
Healthcare, Milton Keynes, United Kingdom), after which 30
mL of blood was obtained from a cubital vein (additional details,
as well as inclusion and exclusion criteria, can be found in the
Supplementary Materials). The study was approved by the
United Kingdom UK National Research Ethics Service.
Routine Laboratory
CMV immunoglobulin G (IgG; Architect CMV IgG, Abbot,
Maidenhead, United Kingdom) was measured in the Brighton
and Sussex University Hospital (BSUH) virology laboratory;
CRP (Cobas Tina-quant, CRP HS, Gen. 3, Roche Diagnostics,
Table 1. Custom Peptide Pools Used for T-Cell Stimulation
Pool Protein(s)a Peptides, No.
1 UL55b 224
2 UL83b 138
3 UL86b 340
4 UL122 120
5 UL123 143
6 UL99b 45
7 UL153b 67
8 UL32b 260
9 UL28 92
10 UL48A 281
11 UL48B 281
12 US3 44
13 UL151; UL82 82; 137
14 UL94; US29 84; 113
15 UL103; US32 60; 43
16 US24; UL36 123; 117
a Responses to pools 1 through 16 (covering 19 cytomegalovirus proteins)
were added to derive summated CD4+ and CD8+ T-cell responses.
b Dominant CD4+ T-cell target protein [28].
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Mannheim, Germany) was obtained from the BSUH pathology
laboratories.
Reagents
Puriﬁed CMV lysate (Advanced Biotechnologies Inc, Columbia
MD) was dissolved in dimethyl sulfoxide and used at a ﬁnal con-
centration of 2 µg/mL. Phytohemagglutinin (PHA; Sigma-
Aldrich, Gillingham, United Kingdom), the positive control for
iTreg assays, and SEB (Source, Town, Country), the positive
control for peripheral blood mononuclear cell (PBMC) assays,
were used at ﬁnal concentrations of 5 µg/mL and 1 µg/mL, re-
spectively. Tuberculin (human tuberculin, SSI, Copenhagen,
Denmark) was used at a ﬁnal concentration of 10 µg/mL. Peptide
pools (PepMix, JPT Peptide Technologies, Berlin, Germany) for
each CMV protein (Table 1) were dissolved in dimethyl sulfoxide
(Sigma-Aldrich) and used at a ﬁnal concentration of 1 µg/mL
per peptide for each pool.
Whole-Blood and PBMC Activation Assays
For the present study, CMV-speciﬁc T-cell subsets were ana-
lyzed in 74 older and 39 younger randomly selected volunteers.
Clinical details recorded for older volunteers are provided in
Supplementary Tables 1 and 2. Whole blood was mixed at a
ratio of 1:1 with complete medium, consisting of Roswell Park
Memorial Institute (RPMI) 1640 medium supplemented
with 100 U/mL penicillin, 100 U/mL streptomycin, 2 mM
L-glutamine, and 10% fetal calf serum (Gibco, Life Technolo-
gies, Paisley, United Kingdom); stimulated with CMV lysate,
CMV PepMixes, or PHA at the speciﬁed ﬁnal concentrations;
and incubated for 44 hours in a standard incubator.
PBMCs were isolated from heparin blood by density gradient
centrifugation (Ficoll-Hypaque, PLUS Healthcare, Bucking-
hamshire, United Kingdom), washed twice with phosphate-
buffered saline (PBS), and resuspended in complete medium.
PBMCs (106 cells per tube) were stimulated in the presence of
anti-CD107 antibody, monensin (Golgistop, BD Biosciences),
and one of the stimulants (positive control; one of 16 different
PepMix solutions, CMV lysate, or tuberculin) for 2 hours
before the addition of brefeldin A (Sigma-Aldrich). Incubation
was stopped after an additional 14 hours.
Whole blood was stained with monoclonal antibodies to
lineage markers CD3 and CD4 (BioLegend, Cambridge Bio-
science, Cambridge, UK), Treg markers CD25 and CD39, and
the activation marker CD134 (BD Biosciences) for 30 minutes
at 4°C; ﬁxed and lysed (ﬂuorescence-activated cell sorter
[FACS] lysing solution, BD Biosciences); and washed twice.
PBMCs were surface stained with monoclonal antibodies to
lineage markers (CD3, CD4, and CD8, BD Biosciences) and
memory markers (CD27, BD Biosciences; and CD45RA, Beck-
manCoulter,HighWycombe,UnitedKingdom).Theywere then
ﬁxed and permeabilized using FACS lysing solution and FACS
permeabilization solution 2, respectively (BD Biosciences);
stained intracellularly for the activation markers IL-2, TNF-α,
IFN-γ, and CD154; and washed twice. All samples were stored
at 4°C in the dark before acquisition. Additional details are
available in the Supplementary Materials.
Cell Acquisition
Cells were analyzed on an LSRII ﬂow cytometer, using FACS-
Diva software, version 6.1 (BD Biosciences), and FlowJo soft-
ware, version 9 (TreeStar, Ashland, USA).
Separate gates were set for each activation marker on CD4+
and CD8+ T cells (ie, IL-2, degranulation, CD154, TNF-a, and
IFN-γ). Boolean gates were used to identify functional combina-
tions of markers. The sum of all Boolean gates represents the per-
centage of cells displaying at least 1 of the markers; these were
termed “activated effector T cells” in this study. Whole-blood
assays were analyzed with respect to CD25, CD39, and CD134
staining of CD4+ T cells, and Boolean gates were used for each
marker as described above (Supplementary Figure 1). Values for
unstimulated samples (negative control) were subtracted from
those for stimulated samples for each individual gate.
Suppression Assays
PBMCs were stimulated (for 44 hours at 37°C) with the UL83
peptide pool and stained with T-cell lineage and Treg markers.
Antigen-induced iTregs (CD4+CD25+CD39+CD134+), nonres-
ponding CD4+ T cells (CD4+CD25−), and CD3− accessory cells
were sorted (Aria-Icell-sorter, BD). After sorting, T-cell popula-
tions were rested in culture medium with IL-2 (100 IU/mL,
Sigma-Aldrich), whereas accessory cells were stored at −80°C.
Responder cells were labeled with PKH67 (Sigma-Aldrich) ac-
cording to the manufacturer’s instructions, and 20 000 cells/well
were plated in 96-well U-bottomed plates (Thermo Fisher Scien-
tiﬁc, Nunc, Denmark). iTregs were added to responder cells at
ratios of 1:1 and 1:10 (Tr:Te). A total of 50 000 accessory cells
were added to each well. Cells were plated (200 µL/well) with 0.5
µg/mL soluble anti-CD3 OKT3 (BD Biosciences) or peptide-
pool UL83 for restimulation. Positive (only responder cells, stim-
ulant, and antigen-presenting cells) and negative proliferation
controls (no restimulation) were run in parallel. On day 3, all
cells were washed with FACS buffer (PBS, 0.5% bovine serum
albumin, and 0.1% sodium azide) before staining. Proliferation
of CD4+ responder cells was identiﬁed on the basis of decreasing
PKH67 expression, as described elsewhere [29].
Statistical Analysis
SPSS-20 was used for analysis. A 2-sided P value of < .05 was
considered statistically signiﬁcant. Non–log-transformed T-cell
subset percentages were compared using the Mann-Whitney
test for independent samples. Log transformation of T-cell
subset percentages was used to improve the normality of the
distributions. For the calculation of Pearson correlation coefﬁ-
cients (SPSS bivariate correlation procedure), log-transformed
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Figure 1. CD25+CD39+CD134+ CD4+ T cells result from short term ex vivo activation with speciﬁc antigens and coexpress the regulatory T-cell (Treg)
marker Foxp3. Panels show experiments in a cytomegalovirus (CMV)–positive donor (A) and a CMV-negative donor (B). Whole blood was stimulated with
medium alone (negative control; unstimulated), CMV lysate, the CMV UL83 peptide pool, and phytohemagglutinin (PHA; positive control). CD39+ cells are
not signiﬁcantly increased by CMV lysate or UL83 stimulation but are strongly increased by PHA stimulation. Note that CD134 is upregulated in response
to CMV antigens in the CMV-positive participant but not the CMV-negative participant (second row in A and B). C, A representative experiment in an older
CMV-positive participant using CMV-lysate stimulation and negative control is shown. Plots show CD4/CD39 staining (left), CD25/Foxp3 staining (middle),
and CD134/Foxp3 staining (right). Percentages of relevant subsets as the percentage of CD4+ T cells are shown in bold in unstimulated (middle, top), and
CMV lysate–stimulated replicates (middle, bottom). The increase of 0.89% of Foxp3+ cells in terms of CD4+ T cells is the maximum contribution that short-
term activation could have made to the Foxp3+CD134+ subset seen after stimulation (right), accounting for a maximum of 48% of these cells. The results
shown are representative of 3 independent experiments.
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T-cell subset percentages were used (for correlations between
T-cell subsets, as well as between T-cell subsets and diastolic
blood pressure and mean arterial blood pressure). Unadjusted
and adjusted linear regression models were used to evaluate
factors associated with diastolic blood pressure and mean arte-
rial blood pressure, using the SPSS UNIANOVA procedure
(using log-transformed T-cell subset percentages).
RESULTS
CD25+CD39+CD134+CD4+ T Cells Are Proper iTregs and Share
Antigen Speciﬁcity With Conventional CD4+ T cells
The expression of CD25 and CD39 (canonical Treg markers) on
Tregs before antigen-speciﬁc activation is the basis of iTreg
detection by the novel method used in this study. Because CD134
is upregulated following CMV-speciﬁc activation, the CMV-
speciﬁc portion of the regulatory subset is revealed as CD25+
CD39+CD134+ cells (Figure 1A and 1B and Supplementary
Figure 1). A large proportion of these cells additionally express
the hallmark Treg marker Foxp3. Some non-Tregs may express
Foxp3+ de novo as a result of short-term activation; however,
when calculated as the difference in Foxp3+ cells between unsti-
mulated and stimulated cells (0.89% of CD4+ T cells in the
example in Figure 1C), these accounted for only about 25% of all
Foxp3+ cells after stimulation, conﬁrming the majority expressed
FoxP3 independently of short-term stimulation.
To examine the ability of CD25+CD39+CD134+CD4+ T cells
to suppress T-cell proliferation ex vivo, we isolated this subset
Figure 2. CD39+CD25+CD134+CD4+ inducible regulatory T cells (iTregs) are able to suppress autologous CD4+ T-cell proliferation. The ability of UL83-
stimulated CD39+CD25+CD134+CD4+ iTregs to suppress proliferation was tested after sorting them from peripheral blood mononuclear cells by a ﬂuores-
cence-activated cell sorter and resting them in high-dose interleukin 2 for 2 days. For the suppressor assay iTregs (Tr) were cocultured with PKH67-stained
CD4+CD25− responder cells (Te) and stimulated with soluble anti-CD3 antibody or UL83 (pp65) peptide pool in the presence of autologous CD3− T cells as
antigen-presenting cells. iTregs were added at Tr:Te ratios of 1:1 and 1:10. Responder cell proliferation in the absence of Tregs or in the absence of stimu-
lation were used as positive and negative controls, respectively. Histograms show increasing lipid dye dilution (PKH67) from right to left. Responder cell
proliferation was measured as the percentage of cells with decreased PKH67 staining.
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from CMV-stimulated PBMCs, using FACS. In the example
(Figure 2), UL83 (pp65)–stimulated PBMCs of a good UL83
responder were sorted into CD25+CD39+CD134+CD4+ iTregs
and CD25−CD4+ responder T cells. The isolated iTregs were
cocultured with UL83-stimulated or anti-CD3–stimulated au-
tologous responder T cells for 3 days. Both antigen-speciﬁc
(UL83) and non–antigen-speciﬁc (anti-CD3) proliferation was
suppressed effectively. The suppressor activity of CMV-
induced CD25+CD39+CD134+ iTregs was conﬁrmed in 3 addi-
tional donors, providing suppression of the same magnitude.
Finally, to explore the protein speciﬁcity of CMV-speciﬁc
iTregs, we studied their responsiveness to the 6 most dominant
target antigens of conventional CD4+ T cells: UL55, UL86,
UL83, UL32, UL99, and UL153 (Figure 3A and 3B) [28, 30]. All
tested peptide pools contributed to the response, and the sum
of all responses correlated highly with that induced by CMV
lysate (r = 0.671; P = .000; Figure 3C). This suggested that that
the pools captured most of the lysate-induced response and
that the same antigens that commonly induce effector respons-
es also induce iTreg responses.
To obtain a reliable measure of the total size of the responses
of CD4+ and CD8+ effector T cells to CMV, we summated the
responses to 19 different CMV peptide pools (aggregated T-cell
response). These 19 pools contained the 6 most important
CD4+ T-cell antigens listed above and the 15 most important
CD8+ T-cell antigens (overlapping by UL83 and UL99) as pre-
viously described (Table 2) [28]. For CD4+ T cells, the CMV
lysate–induced response was used in addition. We deﬁned “ac-
tivated T cells” as T cells displaying at least 1 of the following
activation markers: IL-2 production, CD154 upregulation, de-
granulation, and IFN-γ or TNF-α production [31]. Interestingly,
the frequencies of iTregs were correlated with the conventional
Figure 3. CD39+CD25+CD134+CD4+ inducible regulatory T cells (iTregs) are induced by the same antigens that commonly induce effector responses. The
induction of iTregs was studied in whole-blood assays of cytomegalovirus (CMV)–positive young donors (A) and older donors (B) in response to CMV
peptide pools including the 6 most dominant CMV CD4+ T-cell target antigens (UL55, UL86, UL83, UL32, UL99, and UL153). CMV UL83 (pp65) appeared to
elicit the biggest iTreg responses in both young and older participants. C, The dot plot shows the relationship between the sum (Σ) of the CMV peptide
pool–induced iTreg responses and the CMV lysate–induced iTreg response. D, A signiﬁcant correlation between the CD8+ effector T-cell response to CMV
(ie, the summated CD8+ effector T-cell responses to 19 different CMV proteins) and CMV lysate–induced CD4+ iTregs was observed across the whole
CMV-positive population sample.
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aggregate CD8+ T-cell response (0.375; P = .011; Figure 3D) but
not the CD4+ T-cell response to virus lysate (r = 0.106; P = not
signiﬁcant) or the aggregate CD4+ T-cell response (r = −0.011;
P = not signiﬁcant).
CMV-Speciﬁc iTreg Frequencies Are Increased at Older Ages,
Particularly in Older Women
We initially observed that numbers of CD25+CD39+CD4+
T cells, referred to here simply as Tregs because no speciﬁc stim-
ulation was used, were signiﬁcantly increased at older ages (P =
.002; Figure 4A).The actual extent of CMV-speciﬁc iTreg
expansion was revealed by CMV lysate stimulation; CMV-
responsive but not tuberculin-responsive iTregs were signiﬁ-
cantly higher in older than young participants (P = .009 vs P =
.478, respectively; Figure 4B–D). Interestingly, the highest fre-
quencies of CMV-induced iTregs were found in older women.
This was not found with tuberculin-induced iTregs (Figure 4E),
indicating that this highly signiﬁcant sex-associated difference
(Figure 4F) was CMV speciﬁc. Meanwhile, iTreg induction in
the younger group was much smaller, with no signiﬁcant sex-
associated difference (P = .230).
Absolute counts of CMV-induced iTregs were not calculated,
since the measurements are performed following 44 hours of ex
vivo stimulation. To explore a possible association between the
relative increase of iTregs in older people and a relative loss of
naive CD4+ T cells for example, we analyzed the distribution of
the CD4+ T-cell subsets determined by the expression of classic
memory markers, CD27 and CD45RA, in each CMV-positive
individual, including naive (CD27+/CD45RA+), central
memory (CD27+/CD45RA−), effector memory (CD27−/
CD45RA−), and revertant memory (CD27−/CD45RA+) cells,
as previously described [31], and determined their relationship
with iTregs in CMV-positive individuals across the population
sample (bivariate correlation). The analysis was done for both
non–CMV-reactive and CMV-reactive CD4+ T cells (ie, those
expressing none or at least 1 of 5 analyzed activation markers
following CMV-lysate stimulation, respectively). However,
none of these correlations proved signiﬁcant (r range, −0.161
to 0.051), suggesting that the relative increase of iTregs is not
associated with the relative decline of any speciﬁc conventional
CD4+ T-cell naive/memory subset.
Frequencies of iTregs and CD8+ Effector T Cells Are Associated
With Higher Blood Pressure
As a basic measure of vascular status, standardized diastolic
blood pressure, systolic blood pressure, and mean arterial blood
pressure were determined in all individuals at the time of re-
cruitment. Mean arterial blood pressure was calculated as
follows: [diastolic blood pressure] + [0.33 × (systolic blood pres-
sure – diastolic blood pressure)] [32]. Because we wondered
whether the immune response to CMV might have an effect on
vascular health at older ages, we focused our analysis on CMV-
infected older individuals (additional characteristics are avail-
able in Supplementary Table 1). Initial exploratory analysis
testing simple bivariate correlations observed signiﬁcant associ-
ations between CMV-induced iTregs and mean arterial blood
pressure (r = 0.330; P = .033), as well as diastolic blood pressure
(r = 0.304; P = .05). Slightly stronger associations were found for
CD8+ effector T cells (r = 0.411 [P = .018] and r = 0.478 [P =
.005] for mean arterial blood pressure and diastolic blood pres-
sure, respectively). There was no such correlation for CD4+ ef-
fector T cells, and none of the above T-cell subsets correlated
with systolic blood pressure. Interestingly, correlations between
CMV-induced iTregs and blood pressure were much stronger
in women (r = 0.586 [P = .003] and r = 0.599 [P = .003] for
mean arterial blood pressure and diastolic blood pressure, re-
spectively) than in men (r = 0.104 [P = not signiﬁcant] and r =
−0.094 [P = not signiﬁcant] for mean arterial blood pressure
and diastolic blood pressure, respectively). To allow for a valid
and systematic analysis of the size of CMV-speciﬁc T-cell
subsets on blood pressure, we created a linear regression model
including mean arterial blood pressure or diastolic blood pres-
sure as the dependent variable with sex, regular tobacco
smoking (any time in the present or past), current hypertensive
medication use, and BMI as covariates expected to affect blood
pressure. Because CRP is a marker of inﬂammation, it was
Table 2. Effect of Cytomegalovirus-Inducible Regulatory CD4+
T Cells (iTregs) on Blood Pressure
Factor
Parameter
Estimate (95% CI) P
Mean arterial blood pressure
Smoker 3.49 (−2.67, 9.64) .257
Male sex −38.45 (−91.78 to 14.88) .151
Age 0.25 (−.14 to .64) .202
Body mass index 0.19 (−.61 to .99) .625
Antihypertensive 1.44 (5.19–8.06) .662
CD4+ iTreg count,a per
10-fold increase
20.72 (7.03–34.41) .004
Sex-associated CD4+ iTreg
frequencyb
−18.40 (−41.80 to 4.99) .119
Diastolic blood pressure
Smoker 3.09 (−3.54 to 9.72) .349
Male sex −62.14 (−119.59 to −4.70) .035
Age −0.04 (−.45 to .38) .858
Body mass index 0.44 (−.42 to 1.30) .301
Antihypertensive 1.86 (−5.28 to 8.99) .600
CD4+ iTreg count, per
10-fold increase
21.50 (6.75–36.25) .006
Sex-associated CD4+
iTreg frequencya,b
−28.07 (−53.27 to −2.87) .030
Abbreviation: CI, confidence interval.
a T-cell subset percentages were log transformed for linear regression analysis.
b Interaction term.
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unclear whether it was a confounder or mediator, and models
were tested with and without adjustment for CRP level. CMV-
induced iTregs and CD8+ effector cells were signiﬁcantly corre-
lated both across the whole population sample (Figure 3D) and
in older people (r = 0.403; P = .020) and were, therefore, used
alternately in the models to avoid collinearity. Linear regression
analysis conﬁrmed a signiﬁcant effect of the size of both T-cell
subsets on mean arterial blood pressure (Table 2) and diastolic
blood pressure (Table 3). Because adjustment for CRP level had
no signiﬁcant effect on the model, the data shown are unadjust-
ed for CRP level. With regard to mean arterial blood pressure,
the interaction between sex and CMV-induced iTregs was not
signiﬁcant; however, this interaction was signiﬁcant for dia-
stolic blood pressure.
DISCUSSION
This study identiﬁed a novel, striking link between CMV-spe-
ciﬁc cellular immunity and vascular changes in older life. The
vast majority of CMV-infected people had CMV-speciﬁc CD4+
T cells in their peripheral blood that displayed the hallmarks of
iTregs and whose frequency was signiﬁcantly associated with
Figure 4. Both CD25+CD39+CD4+ regulatory T cells (Tregs) and cytomegalovirus (CMV)–speciﬁc inducible Tregs (iTregs) are signiﬁcantly expanded in
older participants, and their frequencies expose a sex-based difference in older age. Tregs, as well as CMV-speciﬁc or tuberculin-speciﬁc iTregs, were ana-
lyzed by ﬂow cytometry in young and older individuals following ex vivo antigen-speciﬁc stimulation; medium alone was used as negative control. A, A sig-
niﬁcant difference in CD4+CD25+CD39+ Treg frequencies between young donors (n = 39) and older donors (n = 74) was observed in the absence of
stimulation. B, CD25+CD39+CD134+ CMV-speciﬁc iTregs were signiﬁcantly higher in older CMV-positive participants, compared with young CMV-positive
participants, following ex vivo antigen-speciﬁc stimulation with CMV lysate. C, Background levels in CMV-negative participants. D, There was no such dif-
ference in regard to tuberculin-speciﬁc iTregs (including CMV-positive and CMV-negative donors). E, When the same analysis was done looking separately
at men and women, frequencies were clearly higher in older women than in older men, whereas no signiﬁcant increase with age-based or sex-based dif-
ferences was seen with respect to tuberculin-speciﬁc iTregs. F, The difference in CMV-induced iTregs between CMV-positive older women and men is stat-
istically signiﬁcant. Abbreviations: Stim, stimulated; unstim, unstimulated.
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both mean arterial blood pressure and diastolic blood pressure
in a linear regression model. The frequencies of CMV-speciﬁc
CD8+ effector T cells were highly correlated with these regula-
tory-type CD4+ T cells and, likewise, signiﬁcantly associated
with mean arterial blood pressure and diastolic blood pressure.
These observations point to a direct link between quantitative
measurements of CMV-speciﬁc immunity and functional vas-
cular parameters. These ﬁndings were not explained by con-
founders such as age, inﬂammation (ie, CRP level), BMI,
smoking history, or use of antihypertensive medication.
The novel CD4+ T-cell subset we identiﬁed displayed the
classic Treg marker Foxp3 to a large extent and suppressed both
CMV and anti–CD3-induced proliferation of responder cells,
making it a regulatory subset both by phenotype and function.
The fact that its antigen speciﬁcity was demonstrated by CD134
upregulation convinced us that these cells are a type of CMV-
induced iTreg. We further showed that these iTreg responses
were dominated by the same antigens as CD4+ effector T-cell re-
sponses [28], supporting the concept that these are derived from
mature CD4+ T cells rather than natural Tregs [33].
CMV-speciﬁc effector T cells were measured as the aggregate
CD8+ and CD4+ effector T-cell response to 19 different CMV
antigens, of which 6 were most relevant for the CD4+ effector
response and 15 were most relevant for the CD8+ effector re-
sponse, as previously shown [28]. This was an important exper-
imental detail, particularly in terms of CD8+ T cells, since the
size of the response to single proteins does not generally repre-
sent the size of the CMV-speciﬁc CD8+ T-cell response as a
whole [28, 34]. Moreover, CMV lysate is not a good alternative
stimulus for CD8+ T cells because it does not induce represen-
tative CD8+ T-cell responses [30].
The association between CMV-speciﬁc CD8+ T cells and
blood pressure was striking from a clinical point of view and in
agreement with a published report linking the levels of CMV-
speciﬁc CD8+ T cells with carotid intima media thickness [19].
The observed association between the frequencies of these cells
and blood pressure probably reﬂects the immune response to
CMV protein expression in endothelial cells that might result
from endothelial infection or antigen delivery by monocytes to
sites of vascular injury [8, 11]. Whether the action of CD8+
T cells is direct (as in cytotoxicity) or indirect remains to be es-
tablished, but there is some evidence that T cells can adhere to
infected endothelium and that class I MHC is upregulated in
CMV-infected endothelial cells [14, 15], both of which would
support a direct cell contact-mediated effect. Analogous to
what is known from hepatitis B and C, iTregs may be induced
(possibly at the expense of conventional CD4+ effector T cells)
to dampen effector responses directed at CMV-infected endo-
thelium [13]. A recent report that Tregs can attenuate athero-
sclerosis appears to support this [22], but answering this
question deﬁnitively will require additional studies.
Interestingly, the marked changes of the immune system
in terms of composition and function, previously termed
“immune risk phenotype,” include large CD8+ T-cell expan-
sions that are believed to be CMV speciﬁc to some extent, but
this was never conclusively addressed, whereas CMV-induced
iTregs were not assessed in these studies [35]. Our ﬁndings are,
therefore, of major interest, because the main reason why CMV
is thought to decrease survival in the older population is its as-
sociation with increased vascular pathology [3, 4]. Of note,
CMV infection has been reported to have additional direct
effects on blood pressure, both in humans and in animal
models [36, 37]. These seem to be independent of the immune
response and may contribute independently to vascular
changes in older CMV-infected people.
We currently cannot answer why, in our study, older women
had higher numbers of CMV-induced iTregs than older men,
but a more successful induction of iTregs in women may con-
tribute to the delay of signiﬁcant cardiovascular events by
driving a more chronic process. As a result of that, we might
see increased vascular stiffness (both mean arterial blood pres-
sure and systolic blood pressure correlated with iTregs) but not
major damage.
In conclusion, our study provides new and compelling evi-
dence of a quantitative link between CMV-speciﬁc cellular im-
munity and blood pressure or, indirectly, vascular stiffness in
older age. We also have identiﬁed a novel CMV-speciﬁc CD4+
T-cell subset with features of Tregs and potential involvement
in attenuating effector T-cell responses. Preferential induction
of this subset in older women might explain some of the
Table 3. Effect of Cytomegalovirus-Speciﬁc CD8+ Effector
T cells and Blood Pressure
Factor
Parameter
Estimate (95% CI) P
Mean arterial blood pressure
Smoker −0.17 (−7.13 to 6.79) .961
Male sex 2.17 (−4.60 to 8.95) .513
Age 0.11 (−.33 to .55) .607
Body mass index 0.43 (−.47 to 1.33) .335
Antihypertensive −2.13 (−9.08 to 4.81) .532
CD8+ effector T-cell count,a
per 10-fold increase
8.31 (2.20–14.42) .010
Diastolic blood pressure
Smoker 0.12 (−7.52 to 7.77) .974
Male sex 1.02 (−6.42 to 8.46) .780
Age −0.17 (−.65 to .32) .481
Body mass index 0.61 (−.38 to 1.61) .213
Antihypertensive −1.94 (−9.57 to 5.70) .604
CD8+ effector T-cell count,a
per 10-fold increase
9.51 (2.80–16.22) .008
Abbreviation: CI, confidence interval.
a T-cell subset percentages were log transformed for linear regression
analysis.
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sex-associated differences seen in regard to cardiovascular com-
plications. Together, these ﬁndings may indicate that CMV has
an important role in driving vascular changes in older life that
ultimately affect survival. The level of cellular immunity to
CMV might become an important target for intervention in
the future, because it is doubtful that the huge CMV-speciﬁc
T-cell expansions observed in some CMV-infected people [31,
38, 39] are actually required to control infection. Understand-
ing the exact interplay between CMV-speciﬁc CD8+ T cells,
regulatory-type CD4+ T cells, and vascular endothelium poses
a new and exciting challenge to the ﬁeld, because cardiovascu-
lar pathology remains the leading cause of death worldwide.
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